Robotic Laparoscopic Radical Prostatectomy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00292019 |
Recruitment Status
:
Completed
First Posted
: February 15, 2006
Last Update Posted
: August 28, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Prostate Cancer | Procedure: Laparoscopic |
Study Type : | Observational |
Actual Enrollment : | 20 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Robotic Laparoscopic Radical Prostatectomy |
Actual Study Start Date : | March 4, 2004 |
Actual Primary Completion Date : | June 30, 2016 |
Actual Study Completion Date : | June 30, 2016 |

Group/Cohort | Intervention/treatment |
---|---|
Robotic prostatectomy
Patients who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robotics.
|
Procedure: Laparoscopic
Patients with prostate cancer who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robots.
|

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 65 Years (Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Informed Consent
- Locally confined, stage T1a, T2a or T2b prostate cancer
- Aged 40-65 and judged by the study doctor to be a suitable candidate for a radical prostatectomy.
- Serum prostate specific antigen equal to or less than 10mg/ml
- Histologically confirmed adenocarcinoma of the prostate
- Gleason score equal to or less than 7
- Life expectancy of greater than 10 years.
- Prostate size on TRUS measurement less than 40 grams
Exclusion Criteria:
- Patients who have undergone prior hormone therapy.
- Patients with a previous transurethral resectioning of the prostate (TURP)
- History of other cancers other than basal cell carcinoma.
- Patients with any prior abdominal surgery.
- Any condition, or history of illness or surgery than, in the opinion of the investigator, might confound the results of the study or pose additional risk to the patient (eg significant cardiovascular conditions)
- Patients with a large median lobe of the prostate. -
Exclusion Criteria:

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00292019
Canada, Ontario | |
London Health Sciences Centre | |
London, Ontario, Canada, N6A 4G5 |
Principal Investigator: | Joseph Chin, MD< FRCSC | London Health Sciences Centre |
Responsible Party: | Lawson Health Research Institute |
ClinicalTrials.gov Identifier: | NCT00292019 History of Changes |
Other Study ID Numbers: |
R-04-030 10280 |
First Posted: | February 15, 2006 Key Record Dates |
Last Update Posted: | August 28, 2017 |
Last Verified: | August 2017 |